Lupin Unit Boosts Philippines Stake in $39.6M Multicare Pharma Deal

HEALTHCAREBIOTECH

Overview

Lupin Ltd. is increasing its stake in the Philippines. Its Dutch unit, Nanomi B.V., will buy an additional 43.38% of Multicare Pharmaceuticals Philippines, Inc. (MPPI) for up to $39.6 million. This acquisition aims to improve Lupin's market position, integrate operations more deeply, and create long-term value. The deal is expected to close by May 2026.

Expanding Philippines Operations

Lupin Ltd. is strengthening its foothold in the Philippine pharmaceutical market. Its wholly-owned Dutch subsidiary, Nanomi B.V., has agreed to buy 11,794,497 shares of Multicare Pharmaceuticals Philippines, Inc. (MPPI), representing a 43.38% stake.

This move aims to enhance Lupin's market position and help integrate MPPI's operations. Nanomi B.V. already owns a majority 56.28% stake in MPPI, which handles trading, importing, marketing, and distributing pharmaceutical products and medical devices in the Philippines. The new purchase will bring Lupin's consolidated ownership in MPPI close to full control, allowing for greater strategic flexibility and unlocking long-term value.

Deal Terms and Timeline

The deal involves a cash payment of up to $39.6 million. Lupin confirmed the acquisition is a related party transaction and has received approval from its audit committee. No promoters or their groups have a direct interest in this deal. Ernst & Young Merchant Banking Services LLP provided a valuation report to ensure the transaction is at fair market value.

Completion is targeted for the end of May 2026, once certain conditions are met. This expansion highlights Lupin's commitment to growing its international business and increasing its share in key emerging markets.

Disclaimer:This content is for informational purposes only and does not constitute financial or investment advice. Readers should consult a SEBI-registered advisor before making decisions. Investments are subject to market risks, and past performance does not guarantee future results. The publisher and authors are not liable for any losses. Accuracy and completeness are not guaranteed, and views expressed may not reflect the publication’s editorial stance.